Physician profile
Derwin Pearson Gray
NPI 1326050964
$31,883.42
in general payments reported to CMS, 2019-2025
35 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $229 · 2021: $1,786 · 2022: $423 · 2023: $565 · 2024: $4,593 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $22K · Travel and Lodging: $4,402 · Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $22,000.00 |
| Travel and Lodging | $4,401.52 |
| Food and Beverage | $1,952.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $27,725.23 | 2019-2025 | |
| Acessa Health INC. | $1,192.69 | 2021 | |
| Abbvie INC. | $984.38 | 2019-2023 | |
| Astellas Pharma US INC | $407.01 | 2020-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $166.39 | 2019-2025 | |
| Organon LLC | $154.39 | 2021-2024 | Nexplanon |
| Sumitomo Pharma America, INC. | $132.71 | 2023-2024 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $122.86 | 2019-2025 | Wallach Cryosurgical Equipment, Sos, Mara Console |
| Minerva Surgical, INC | $110.24 | 2019-2024 | |
| Optumhealth Care Solutions, LLC | $98.23 | 2024-2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Exeltis, USA INC. | $91.38 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $91.15 | 2019-2021 | |
| Shield Therapeutics INC | $66.40 | 2025 | |
| Myovant Sciences INC. | $57.33 | 2022 | |
| Biogen, INC. | $51.08 | 2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $50.31 | 2024 | Injectafer |
| Amag Pharmaceuticals, INC. | $40.84 | 2019 | |
| Axonics, INC. | $40.62 | 2024 | Bulkamid |
| Novo Nordisk INC | $37.63 | 2019-2023 | Wegovy |
| Covidien Lp | $27.93 | 2019 | |
| Smith+Nephew, INC. | $26.76 | 2022 | |
| Meditrina | $24.96 | 2023-2024 | |
| Alydia Health | $24.62 | 2021 | |
| Mayne Pharma Commercial LLC | $19.35 | 2021 | |
| Avanos Medical | $17.85 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $16.54 | 2022 | |
| Baxter Healthcare | $16.42 | 2022 | |
| Merck Sharp & Dohme LLC | $16.02 | 2019 | |
| Channel Medsystems, INC. | $13.58 | 2023 | |
| Ferring Pharmaceuticals INC. | $12.53 | 2019 | |
| Therapeuticsmd, INC. | $12.15 | 2020 | |
| Avion Pharmaceuticals | $11.71 | 2022 | |
| Lupin INC. | $11.10 | 2019 | |
| Allergan, INC. | $11.03 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derwin Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.